NasdaqGM:JANXBiotechs
Janux Therapeutics (JANX) Losses Reach US$113.6 Million TTM Reinforcing Bearish Narratives
Janux Therapeutics (JANX) closed FY 2025 with Q4 revenue of US$0 million and a basic EPS loss of US$0.51, alongside a trailing twelve month basic EPS loss of US$1.83 on US$10 million of revenue, with a clear focus on how much growth is costing. Over the past six reported quarters, the company has seen quarterly revenue range from US$0 million to US$13.05 million while basic EPS has moved between losses of US$0.36 and US$0.55, giving investors a detailed view of how the top line and per share...